Loading clinical trials...
Loading clinical trials...
A Phase I Trial to Evaluate the Safety and Efficacy of Addition of Novel Anti-leukemia Agents to Flu/Mel RIC Transplant for High-risk Myeloid Malignancies
Conditions
Interventions
G-CSF
Decitabine
+1 more
Locations
1
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Start Date
July 17, 2025
Primary Completion Date
December 1, 2026
Completion Date
January 1, 2027
Last Updated
March 4, 2026
NCT05564390
NCT03050268
NCT07320235
NCT05417971
NCT06782542
NCT05886049
Lead Sponsor
University of Alabama at Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions